Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Journal of Clinical Oncology2023Vol. 41(19), pp. 3534–3544
Citations Over TimeTop 1% of 2023 papers
Claire Harrison, Jyoti Nangalia, Rebecca H. Boucher, Aimee Jackson, Christina Yap, Jennifer O’Sullivan, Sonia Fox, Isaak Ailts, Amylou C. Dueck, Holly L. Geyer, Ruben A. Mesa, William G. Dunn, Eugene Nadezhdin, Natalia Curto‐García, Anna Green, Bridget S. Wilkins, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Steven Knapper, Josephine Crowe, Frederick Chen, Ioannis Koutsavlis, Anna L. Godfrey, Siamak Arami, Mark W. Drummond, Jenny Byrne, Fiona Clark, Carolyn Mead‐Harvey, E. Joanna Baxter, Mary Frances McMullin, Adam J. Mead
Abstract
The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.
Related Papers
- → JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis(2012)1,766 cited
- → Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly(2012)23 cited
- → Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib(2019)5 cited
- → Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib(2016)
- → Myelofibrosis Management After Ruxolitinib Failure(2019)